Zsolt Talloczy

Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial

Kausik K. Ray, Roel P T Troquay, Frank L.J. Visseren et al. · The Lancet Diabetes & Endocrinology · 2023 · 282 citations · Full text

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study

Jürgen Braun, Xenofon Baraliakos, Atul Deodhar et al. · Lara D. Veeken · 2018 · 136 citations · Full text

Efficacy and Safety of Secukinumab 150 mg with and Without Loading Regimen in Ankylosing Spondylitis: 104-week Results from MEASURE 4 Study

Alan Kivitz, Ulf Wagner, Eva Dokoupilová et al. · Rheumatology and Therapy · 2018 · 117 citations · Full text

Long-term effects of interleukin-17A inhibition with secukinumab in active ankylosing spondylitis: 3-year efficacy and safety results from an extension of the Phase 3 MEASURE 1 trial.

Xenofon Baraliakos, Alan Kivitz, Atul Deodhar et al. · PubMed · 2017 · 91 citations

Immunodeficiencies, Immunology, Immunotherapy +23

Long-term efficacy and safety of secukinumab 150 mg in ankylosing spondylitis: 5-year results from the phase III MEASURE 1 extension study

Xenofon Baraliakos, Jürgen Braun, Atul Deodhar et al. · RMD Open · 2019 · 80 citations · Full text